Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHealthPartners Part B Step Therapy Coverage | Open…
    Ask Trek AI about this page
    CurrentHealthPartnersPolicy N/A

    Medicare Part B Drugs Requiring Step Therapy

    Customize your policy alerts

    Sign up for all HealthPartners policy alerts

    Know when HealthPartners releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines step therapy requirements for Medicare Advantage (HealthPartners) Part B medications, including preferred step agents and criteria for exceptions; applies to HealthPartners Medicare products noted. Affects providers requesting coverage/authorization for Part B drugs for Medicare Advantage members.

    Policy Summary
    PayerHealthPartners
    PolicyMedicare Part B Drugs Requiring Step Therapy
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionFor patients new-to-therapy, prescribe the listed preferred step agent unless documented exception criteria are met and submit required prior authorization demonstrating medical necessity.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Medicare Advantageplan type
    Multipledrug groups
    3 conditionsexception criteria
    Named Medicare productsin-scope plans

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria

    Exceptions to step therapy

    Coverage for a non-preferred product may be authorized when ALL of the following are met:

    Exception criteria for non-preferred product: 1) Medical necessity has been demonstrated based on medical necessity criteria; 2) The patient has been taking a non-preferred medication and is stable on the non-preferred product, OR 3) The patient has tried and failed or has medical contraindications to preferred products.

    Items 2 and 3 are OR-linked as alternative paths to exception

    Provider Actions and Prior Authorization

    Prior Authorization

    Prior authorization required for step therapy

    Patients new-to-therapy must use the preferred step agent; prior authorization may be granted for a non-preferred product only when medical necessity is shown and the exception criteria are met.

    Step Therapy

    Step therapy requirement and preferred agents

    For patients new-to-therapy, use of the preferred medication (the listed step agent) is required. Preferred step agents are specified by drug/group (examples: Inflectra or Renflexis for infliximab; Kanjinti, Ogivri, or Trazimera for trastuzumab; Ruxience or Truxima for rituximab; Mvasi or Zirabev for bevacizumab; Neulasta/Onpro, Fulphila, or Ziextenzo for long-acting G-CSF; Ocular Avastin for many ocular anti‑VEGF products).

    Documentation Required

    Exception documentation requirements

    To authorize a non-preferred product, documentation must demonstrate medical necessity and either that the patient is stable on the non-preferred medication or that the patient has tried and failed, or has medical contraindications to, the preferred products.

    • Documentation must show medical necessity per applicable Medicare NCD/LCD or Benefit Policy Manual criteria.
    • Show stability on the non-preferred product OR trial-and-failure/contraindication to preferred agents.
    Denial Risk

    Step therapy enforcement for new-to-therapy patients

    Coverage for new-to-therapy patients requires use of the preferred step agent unless the exception criteria are met; failure to document step therapy or meet exception criteria may result in denial of coverage.

    Background

    Step therapy is a utilization management approach applied to Medicare Advantage Part B drugs that requires patients who are new-to-therapy to begin treatment with a preferred step agent. This policy applies to HealthPartners Medicare Advantage plans only and references applicable Medicare NCDs/LCDs or the Medicare Benefit Policy Manual for full medical necessity criteria. When medical necessity is met, use of the preferred medication is required for patients who have not previously taken the requested drug; patients already stable on a non-preferred product may continue that therapy if medical necessity criteria are satisfied.

    Coverage for a non-preferred product may be authorized only when ALL of the following are met: 1) medical necessity has been demonstrated based on medical necessity criteria; and 2) the patient is stable on a non-preferred medication, OR 3) the patient has tried and failed or has medical contraindications to preferred products. The policy list of step agents and preferred medications is subject to change; refer to the plan-specific documents for scope and contact Member Services for questions.

    Definitions

    Patient new-to-therapy
    DefinitionA patient who has not yet taken the medication being requested for coverage.
    Applies toStep therapy requirement for Medicare Advantage Part B drugs (patients new-to-therapy must use the preferred step agent unless exception criteria are met).
    Related coverage noteIf medical necessity is met, preferred step agent is required for new-to-therapy patients; continued coverage of non-preferred medications allowed for patients already stable on them if medical necessity criteria are satisfied.
    Where to find more informationReference applicable Medicare NCDs/LCDs or the Medicare Benefit Policy Manual for full medical necessity coverage criteria; contact Member Services for Medicare coverage policy copies.

    Initial Therapy / Step Agent Requirement

    Initial therapy / Step agent requirement

    For patients new-to-therapy the preferred medication (step agent) must be used unless exception criteria are met.

    Initial therapy requirement: New-to-therapy patients must use the listed preferred step agent for the drug class or specific drug unless exception criteria are documented.

    Preferred agents are listed per drug group in the policy text (see step agent list).

    Continuation Therapy

    Continuation therapy

    Patients stable on a non-preferred medication will have continued coverage of the non-preferred medication if other requirements of medical necessity are met.

    Continuation therapy: Continued coverage allowed for patients already stable on a non-preferred medication provided medical necessity criteria are satisfied.

    Documentation of ongoing stability and medical necessity should be provided.

    Step Therapy Table — Preferred Agents by Drug Group

    Drug / Drug GroupPreferred Step Agent (new-to-therapy patients)
    {"text":"Remicade and other infliximab products","status":""},{"text":"Inflectra or Renflexis","status":""}
    {"text":"Herceptin, Herceptin Hylecta, and single‑agent trastuzumab products","status":""},{"text":"Kanjinti, Ogivri, or Trazimera","status":""}
    {"text":"Rituxan and other rituximab products; Enjaymo","status":""},{"text":"Ruxience or Truxima","status":""}
    {"text":"Avastin and other bevacizumab products","status":""},{"text":"Mvasi or Zirabev","status":""}
    {"text":"Long‑acting G‑CSF products (e.g., Udenyca, Nyvepria, Rolvedon, etc.)","status":""},{"text":"Neulasta, Neulasta Onpro, Fulphila, or Ziextenzo","status":""}
    {"text":"IV iron products (e.g., Injectafer, Monoferric, Triferic)","status":""},{"text":"Feraheme, Ferrlecit, Infed, or Venofer","status":""}
    {"text":"Ocular anti‑VEGF agents (e.g., Eylea, Beovu, Lucentis, Susvimo, Vabysmo, etc.)","status":""},{"text":"Ocular Avastin","status":""}
    {"text":"Intra‑articular hyaluronan products (e.g., Durolane, Genvisc, Hyalgan, Supartz, etc.)","status":""},{"text":"Euflexxa, Synvisc, or Synvisc One","status":""}
    {"text":"Lanreotide (Somatuline Depot)","status":""},{"text":"Sandostatin or Sandostatin LAR","status":""}
    {"text":"Pemetrexed products (Pemfexy, Pemrydi RTU, Axtle, etc.)","status":""},{"text":"Generic pemetrexed or Alimta","status":""}
    {"text":"Docivyx and docetaxel products","status":""},{"text":"Generic docetaxel","status":""}
    {"text":"Vectibix","status":""},{"text":"Erbitux","status":""}
    {"text":"Entyvio IV","status":""},{"text":"Inflectra or Renflexis","status":""}
    {"text":"Tepezza","status":""},{"text":"IV steroids (e.g., methylprednisolone)","status":""}

    Biosimilar Preferred Agents

    Billing Rule

    Preferred step agents for infliximab products

    Inflectra or Renflexis are the designated preferred step agents for Remicade and other infliximab products not otherwise listed.

    • Use Inflectra or Renflexis as the step agent for infliximab products unless exception criteria are met.
    Billing Rule

    Preferred step agents for trastuzumab products

    Kanjinti, Ogivri, or Trazimera are the preferred step agents for Herceptin, Herceptin Hylecta, and other single-agent trastuzumab products not otherwise listed.

    • Use Kanjinti, Ogivri, or Trazimera as the step agent for trastuzumab products unless exception criteria are met.
    Policy Summary
    PayerHealthPartners
    PolicyMedicare Part B Drugs Requiring Step Therapy
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionFor patients new-to-therapy, prescribe the listed preferred step agent unless documented exception criteria are met and submit required prior authorization demonstrating medical necessity.
    SourceLink
    On This Page
    Coverage CriteriaProvider Actions and Prior AuthorizationBackgroundDefinitionsInitial Therapy / Step Agent RequirementContinuation TherapyStep Therapy Table — Preferred Agents by Drug GroupBiosimilar Preferred Agents
    Billing Rule

    Preferred step agents for rituximab products and Enjaymo

    Ruxience or Truxima are the preferred step agents for Rituxan and other rituximab products and for Enjaymo when not otherwise listed.

    • Use Ruxience or Truxima as the step agent for rituximab products and Enjaymo unless exception criteria are met.
    Billing Rule

    Preferred step agents for bevacizumab products

    Mvasi or Zirabev are the preferred step agents for Avastin and other bevacizumab products not otherwise listed.

    • Use Mvasi or Zirabev as the step agent for bevacizumab products unless exception criteria are met.